Cargando…
Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
BACKGROUND: Drug manufacturers have developed “evergreening” strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine...
Autores principales: | Vernaz, Nathalie, Haller, Guy, Girardin, François, Huttner, Benedikt, Combescure, Christophe, Dayer, Pierre, Muscionico, Daniel, Salomon, Jean-Luc, Bonnabry, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672218/ https://www.ncbi.nlm.nih.gov/pubmed/23750120 http://dx.doi.org/10.1371/journal.pmed.1001460 |
Ejemplares similares
-
Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines
por: Vernaz, Nathalie, et al.
Publicado: (2016) -
Rethinking cost-effectiveness in the era of zero healthcare spending growth
por: Arbel, Ronen, et al.
Publicado: (2016) -
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021) -
Healthcare spending in the State of Louisiana
por: Kruger, Blake P., et al.
Publicado: (2019) -
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine
por: Girardin, François R., et al.
Publicado: (2018)